RxDoctor Payments Data

Christina Johnson, APRN

Women's Health · Cincinnati, OHNPI 1003400698

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $753 and has fallen 51.8% since, to $363 in 2025. Among women's health clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,240in general payments, 2019–2025

Across 131 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$345
  • AbbVie$244
  • Shield Therapeutics Inc$231
  • Exeltis, USA Inc.$215
  • Astellas Pharma US Inc$136
  • Lilly USA, LLC$135
  • plus $935 from 20 others

What the payments were for

  • Food & beverage$2,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,240 in reported general payments places this provider in the 90th percentile of 333 women's health providers in Ohio.

See all women's health providers in Ohio

Medicare billing

Part B allowed, 2024
$7,004
Medicare patients
48
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$10,794
Estradiol29$2,213
Estradiol (Twice Weekly)Estradiol19$1,990
Medroxyprogesterone Acetate12$222
Alendronate Sodium12$11

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$136$10,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 333 women's health providers in Ohio.

Other women's health in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →